^
Association details:
| Biomarker: | FLT3 D835Y |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients
Excerpt:
The incidence of FLT3-D835 (exon 20) mutations was 3.4% (1 of 29), observed in patient 1 (D835Y)....The D835 patient in this study (1) showed weak transient inhibition consistent with low plasma drug levels (Cmax, 15 ng/ml; data not shown). These data clearly demonstrate that a single dose of SU11248 results in inhibition of FLT3 phosphorylation in a dose-dependent manner in AML patients, with inhibition in all genotype.
DOI:
10.1038/sj.onc.1206543
